|
1
|
Grothey A, Sargent D, Goldberg RM and
Schmoll HJ: Survival of patients with advanced colorectal cancer
improves with the availability of fluorouracil-leucovorin,
irinotecan, and oxaliplatin in the course of treatment. J Clin
Oncol. 22:1209–1214. 2004. View Article : Google Scholar
|
|
2
|
Watanabe T, Itabashi M, Shimada Y, et al:
Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2010 for the treatment of colorectal cancer. Int J Clin
Oncol. 17:1–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Muro K, Boku N, Shimada Y, et al:
Irinotecan plus S-1 (IRIS) versus fluorouracil and folininc acid
plus irinotecan (FOLFIRI) as second-line chemotherapy for
metastatic colorectal cancer: a randomised phase 2/3
non-inferiority study (FIRIS study). Lancet Oncol. 11:853–860.
2010. View Article : Google Scholar
|
|
4
|
Colucci G, Gebbia V, Paoletti G, et al:
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the
treatment of advanced colorectal cancer: a multicenter study of the
Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol.
23:4866–4875. 2005.PubMed/NCBI
|
|
5
|
Tournigand C, André T, Achille E, et al:
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: a randomized GERCOR Study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar
|
|
6
|
Choi YH, Kim TW, Kim KP, et al: A Phase II
study of clinical outcomes of 3-week cycles of irinotecan and S-1
in patients with previously untreated metastatic colorectal cancer:
Influence of the UGT1A1 and CYP2A6 polymorphisms on clinical
activity. Oncology. 82:290–297. 2012. View Article : Google Scholar
|
|
7
|
Kaneko J, Isogai J, Aoyagi H, et al: A
case of unresectable multiple hepatic metastases from colorectal
cancer successfully treated with IRIS (S-1, CPT-11) therapy. Gan To
Kagaku Ryoho. 37:2576–2578. 2010.(In Japanese).
|
|
8
|
Ueda S, Minami Y, Hara Y, Kawano T and
Maekawa K: A case of recurrent rectal cancer with multiple lung
metastases successfully treated with S-1 and CPT-11 combination
chemotherapy. Gan To Kagaku Ryoho. 36:1725–1727. 2009.(In
Japanese).
|
|
9
|
Samejima J, Iwasaki H, Hatori S, et al:
Effectiveness of S-1 plus CPT-11 therapy for an elderly patient
with recurrent colon cancer. Gan To Kagaku Ryoho. 36:1371–1373.
2009.(In Japanese).
|
|
10
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumors. 7th edition.
Wiley-Blackwell; NY: 2009
|
|
11
|
Schmoll HJ, Van Cutsem E, Stein A, et al:
ESMO Consensus Guidelines for management of patients with colon and
rectal cancer. A personalized approach to clinical decision making.
Ann Oncol. 23:2479–2516. 2012. View Article : Google Scholar
|
|
12
|
Komatsu Y, Yuki S, Sogabe S, et al: Phase
II study of combined chemotheraphy with irinotecan and S-1 (IRIS)
plus bevacizumab in patients with inoperable recurrence or advanced
colorectal cancer. Acta Oncol. 51:867–872. 2012. View Article : Google Scholar
|
|
13
|
Kato S, Andoh H, Gamoh M, et al: Safety
verification trial of mFOLFIRI and sequential IRIS + bevacizumab as
first- or second-line therapies for metastatic colorectal cancer in
Japanese patients. Oncology. 83:101–107. 2012.PubMed/NCBI
|
|
14
|
Yamada Y, Yamaguchi T, Matsumoto H, et al:
Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB)
as first-line therapy for patients with metastatic colorectal
cancer. Invest New Drugs. 30:1690–1696. 2012. View Article : Google Scholar
|
|
15
|
Goya T, Miyazawa N, Kondo H, Tsuchiya R,
Naruke T and Suemasu K: Surgical resection of pulmonary metastases
from colorectal cancer. 10-year follow-up. Cancer. 64:1418–1421.
1989.PubMed/NCBI
|
|
16
|
McCormack PM, Burt ME, Bains MS, Martini
N, Rusch VW and Ginsberg RJ: Lung resection for colorectal
metastases. 10-year results. Arch Surg. 127:1403–1406.
1992.PubMed/NCBI
|
|
17
|
Ike H, Shimada H, Ohki S, Togo S,
Yamaguchi S and Ichikawa Y: Results of aggressive resection of lung
metastases from colorectal carcinoma detected by intensive
follow-up. Dis Colon Rectum. 45:468–473. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Farid M, Chowbay B, Chen X, et al: Phase I
pharmacokinetic study of chronomodulated dose-intensified
combination of capecitabine and oxaliplatin (XELOX) in metastatic
colorectal cancer. Cancer Chemother Pharmacol. 70:141–150. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matsuo K, Higuchi M, Sasaki Y, et al:
Analysis of a case of oxaliplatin - induced persistence sensory
neuropathy. Gan To Kagaku Ryoho. 37:551–554. 2010.(In
Japanese).
|
